PDFF Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF. | The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF. | ||
== | ==Meetings== | ||
''' | |||
Approved call summaries:''' | |||
*[[Media:2017_09-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 7, 2017]] | *[[Media:2017_09-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 7, 2017]] | ||
*[[Media:2017_08-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 3, 2017]] | *[[Media:2017_08-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 3, 2017]] | ||
Revision as of 20:31, 22 November 2017
- Co-chairs: Scott Reeder, MD, PhD, Takeshi Yokoo, MD, PhD
- Secretary: Susan Weinmann
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF.
Meetings
Approved call summaries:
PDFF Biomarker Committee Call Summaries Archive